Infliximab maintains durable response and facilitates catch-up growth In luminal pediatric Crohn's disease

Inflammatory Bowel Diseases

Volumn 20, Issue 7, 2014, Pages 1177-1186

  Church, Peter C ^a   Guan, Jack ^a   Walters, Thomas D ^a,b   Frost, Karen ^a,b   Assa, Amit ^a   Muise, Aleixo M ^a,b,c   Griffiths, Anne M ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Crohn's disease; Growth; Infliximab; Pediatric; Response

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CORTICOSTEROID; DIPHENHYDRAMINE; GAMMA GLUTAMYLTRANSFERASE; HYDROCORTISONE; INFLIXIMAB; METHOTREXATE; PARACETAMOL; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; ASSOCIATION; CATCH UP GROWTH; CHILD; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HERPES SIMPLEX; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; INFECTIOUS COMPLICATION; INFUSION RELATED REACTION; INTESTINE RESECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PSORIASIS; REMISSION; SEX DIFFERENCE; TREATMENT RESPONSE; VERRUCA VULGARIS; VIRUS MENINGITIS; WOUND HEALING; AGE; COHORT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; FACTUAL DATABASE; GROWTH; INTESTINE MUCOSA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; ANTIBODIES, MONOCLONAL; CHILD; COHORT STUDIES; CROHN DISEASE; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GROWTH; HUMANS; INTESTINAL MUCOSA; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TREATMENT OUTCOME;

EID: 84905491833     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000083     Document Type: Article

References (34)

1. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873; quiz 1165-1166.
2. Chaparro M, Panes J, Garcia V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose "escalation" in patients losing response. J Clin Gastroenterol. 2011;45:113-118.
3. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a singlecentre cohort. Gut. 2009;58:492-500.
4. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007;13:424-430.
5. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
6. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447.
7. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data. 2000;314:1-28.
8. Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med. 1992;11:1305-1319.
9. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667.
10. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014;146:383-391.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
12. Schreiber S, Colombel JF, Bloomfield R, et al. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582.
13. Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics. 2007;120:e1418-e1425.
14. Gupta N, Cohen SA, Bostrom AG, et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology. 2006;130:1069-1077.
15. Benchimol EI, To T, Griffiths AM, et al. Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universalaccess healthcare system. J Pediatr. 2011;158:960-967. e961-e964.
16. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit. 2008;30:523-529.
17. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254.
18. Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease. J Crohns Colitis. 2013;7:369-376.
19. De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther. 2011;33:243-250.
20. Crombe V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis. 2011;17:2144-2152.
21. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009;15:816-822.
22. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. New Engl J Med. 2010;362:1383-1395.
23. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267.
24. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-1868.
25. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41.e31.
26. Kugathasan S, Judd RH, Hoffmann RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143:525-531.
27. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. New Engl J Med. 2008;359:810-820.
28. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563.
29. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease. Gastroenterology. 2014;146:681-688.
30. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347.
31. de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353-358.
32. Sherlock ME, Walters T, Tabbers MM, et al. Infliximab-induced psoriasis and psoriasiform skin lesions in pediatric Crohn disease and a potential association with IL-23 receptor polymorphisms. J Pediatr Gastroenterol Nutr. 2013;56:512-518.
33. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651-662.
34. Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1612-1617.